Prostaglandin analogues in the anterior eye: Their pressure lowering action and side effects

Experimental Eye Research

Volumn 88, Issue 4, 2009, Pages 786-791

  Cracknell, Kathryn P B ^a   Grierson, Ian ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

aqueous humour dynamics; glaucoma; IOP lowering; iris colour change; prostaglandin analogue; side effect

Indexed keywords

BIMATOPROST; LATANOPROST; MELANIN; PROSTAGLANDIN DERIVATIVE; TRAVOPROST; UNOPROSTONE ISOPROPYL ESTER;

ANTERIOR EYE CHAMBER; BURNING SENSATION; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; DRUG WITHDRAWAL; DRY EYE; EYE COLOR; EYE INFLAMMATION; EYE IRRITATION; EYELASH; EYELASH DARKENING; EYELASH HYPERTRICHOSIS; EYELASH PIGMENTATION; EYELASH THICKENING; EYELID COLOR; EYELID PIGMENTATION; HUMAN; HYPERTRICHOSIS; INTRAOCULAR PRESSURE; IRIS; IRIS DARKENING; IRIS PIGMENTATION; PIGMENTATION; PRIORITY JOURNAL; RETINA MACULA CYSTOID EDEMA; REVIEW; SIDE EFFECT; UVEITIS;

ANTIHYPERTENSIVE AGENTS; EYE DISEASES; HUMANS; HYPERPIGMENTATION; INTRAOCULAR PRESSURE; IRIS DISEASES; PROSTAGLANDINS, SYNTHETIC;

EID: 64249170014     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exer.2008.08.022     Document Type: Review

References (82)

1. Albert D.M., Gangnon R.E., Grossniklaus H.E., Green W.R., Darjatmoko S., and Kulkarni A.D. A study of histopathological features of latanoprost-treated irides with or without darkening compared with non-latanoprost-treated irides. Archives of Ophthalmology 126 (2008) 626-631
2. Albert D.M., Gangnon R.E., Zimbric M.L., Damico C.M., Fisher M.R., Gleiser J., Grossniklaus H.E., and Green W.R. A study of iridectomy histopathologic features of latanoprost- and non-latanoprost-treated patients. Archives of Ophthalmology 122 (2004) 1680-1685
3. Alm A. Prostaglandin derivates as ocular hypotensive agents. Progress in Retinal and Eye Research 17 (1998) 291-312
4. Alm, A., Grierson, I., Shields, M.B. Side effects associated with prostaglandin analogue therapy. Survey of Ophthalmology, in press.
5. Alm A., Schoenfelder J., and McDermott J. A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma. Archives of Ophthalmology 122 (2004) 957-965
6. Alm A., et al. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning - a comparison with timolol. Ophthalmology 102 (1995) 1743-1752
7. Arcieri E.S., Santana A., Rocha F.N., Guapo G.L., and Costa V.P. Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia - a 6-month randomized trial. Archives of Ophthalmology 123 (2005) 186-192
8. Arranz-Marquez E., Teus M.A., Saornil M.A., Mendez M.C., and Gil R. Analysis of irises with a latanoprost-induced change in iris color. American Journal of Ophthalmology 138 (2004) 625-630
9. Bahler C.K., Howell K.G., Hann C.R., Fautsch M.P., and Johnson D.H. Prostaglandins increase trabecular meshwork outflow facility in cultured human anterior segments. American Journal of Ophthalmology 145 (2008) 114-119
10. Bill A. Effects of atropine and pilocarpine on aqueous humour dynamics in cynomologus monkeys (Macaca Irus). Experimental Eye Research 6 (1967) 120-125
11. Bill A. Uveoscleral drainage of aqueous humor: physiology and pharmacology. Progress in Clinical and Biological Research 312 (1989) 417-427
12. Bito L.Z. Prostaglandins: a new approach to glaucoma management with a new, intriguing side effect. Survey of Ophthalmology 41 (1997) S1-S14
13. Bito L.Z., and Baroody R.A. Impermeability of rabbit erythrocytes to prostaglandins. American Journal of Physiology 229 (1975) 1580-1584
14. Bito L.Z., Srinivasan B.D., Baroody R.A., and Schubert H. Non-invasive observations on eyes of cats after long-term maintenance of reduced intraocular-pressure by topical application of prostaglandin-E2. Investigative Ophthalmology & Visual Science 24 (1983) 376-380
15. Brown S.M. Increased iris pigment in a child due to latanoprost. Archives of Ophthalmology 116 (1998) 1683-1684
16. Camras C.B., et al. Latanoprost, a prostaglandin analog, for glaucoma therapy - efficacy and safety after 1 year of treatment in 198 patients. Ophthalmology 103 (1996) 1916-1924
17. Camras C.B., et al. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma - a six-month, masked, multicenter trial in the United States. Ophthalmology 103 (1996) 138-147
18. Camras C.B., Neely D.G., and Weiss E.L. Latanoprost-induced iris color darkening: a case report with long-term follow-up. Journal of Glaucoma 9 (2000) 95-98
19. Chiba T., Kashiwagi K., Ishijima K., Furuichi M., Kogure S., Abe K., Chiba N., and Tsukahara S. A prospective study of iridial pigmentation and eyelash changes due to ophthalmic treatment with latanoprost. Japanese Journal of Ophthalmology 48 (2004) 141-147
20. Chiba T., Kashiwagi K., Kogure S., Abe K., Shibuya T., Furuichi M., Iijima H., and Tsukahara S. Iridial pigmentation induced by latanoprost ophthalmic solution in Japanese glaucoma patients. Journal of Glaucoma 10 (2001) 406-410
21. Chou S.Y., Chou C.K., Kuang T.M., and Hsu W.M. Incidence and severity of iris pigmentation on latanoprost-treated glaucoma eyes. Eye 19 (2005) 784-787
22. Cracknell K.P.B., Farnell D.J.J., and Grierson I. Monte Carlo simulation of latanoprost induced iris darkening. Computer Methods and Programs in Biomedicine 87 (2007) 93-103
23. Cracknell K.P.B., Grierson I., and Hogg P. Morphometric effects of long-term exposure to latanoprost. Ophthalmology 114 (2007) 938-948
24. Cracknell K.P.B., Grierson I., Hogg P., Appleton P., and Pfeiffer N. Latanoprost-induced iris darkening: a morphometric study of human peripheral iridectomies. Experimental Eye Research 77 (2003) 721-730
25. Crawford K., and Kaufman P.L. Pilocarpine antagonizes prostaglandin-F2-alpha-induced ocular hypotension in monkeys - evidence for enhancement of uveoscleral outflow by prostaglandin-F2-alpha. Archives of Ophthalmology 105 (1987) 1112-1116
26. Crawford K., Kaufman P.L., and Gabelt B.T. Effects of topical Pgf2-alpha on aqueous-humor dynamics in cynomolgus monkeys. Current Eye Research 6 (1987) 1035-1044
27. Feldman R.M. Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension. Journal of Ocular Pharmacology and Therapeutics 19 (2003) 23-35
28. Gabelt B.T., and Kaufman P.L. Prostaglandin-F-2-alpha increases uveoscleral outflow in the cynomolgus monkey. Experimental Eye Research 49 (1989) 389-402
29. Goldberg I., Cunha-Vaz J., Jakobsen J.E., Nordmann J.P., Trost E., and Sullivan E.K. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. Journal of Glaucoma 10 (2001) 414-422
30. Grierson I., Lee W.R., and Albert D.M. The fine structure of an iridectomy specimen from a patient with latanoprost-induced eye color change. Archives of Ophthalmology 117 (1999) 394-396
31. Grierson I., and Pfeiffer N. The morphology of irides treated with latanoprost. In: Diestelhorst M. (Ed). Prostaglandins in Ophthalmology (1998), Kaden Verlag, Heidelberg
32. Grierson I., Pfeiffer N., Cracknell K.P.B., and Appleton P. Histology and fine structure of the iris and outflow system following latanoprost therapy. Survey of Ophthalmology 47 (2002) S176-S184
33. Hayashi M., Yablonski M.E., and Bito L.Z. Eicosanoids as a new class of ocular hypotensive agents .2. comparison of the apparent mechanism of the ocular hypotensive effects of A-type and F-type prostaglandins. Investigative Ophthalmology & Visual Science 28 (1987) 1639-1643
34. Hellberg M.R., et al. Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist. Survey of Ophthalmology 47 (2002) S13-S33
35. Higginbotham E.J. 1-year comparison of the new prostamide AGN 192024 with timolol for the management of glaucoma and ocular hypertension. Investigative Ophthalmology & Visual Science 42 (2001) S559
36. Higginbotham E.J., Schuman J.S., Goldberg I., Gross R.L., Vandenburgh A.M., Chen K., and Whitcup S.M. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Archives of Ophthalmology 120 (2002) 1286-1293
37. Hinz B., Rosch S., Ramer R., Tamm E.R., and Brune K. Latanoprost induces matrix metalloproteinase-1 expression in human nonpigmented ciliary epithelial cells through a cyclooxygenase-2-dependent mechanism. Faseb Journal 19 (2005) 1929-1953
38. Hollo G. The side effects of the postaglandin analogues. Expert Opinion on Drug Safety 6 (2007) 45-52
39. Hu D.N., Stjernschantz J., and Mccormick S.A. Effect of prostaglandins A(2), E-1, F-2 alpha and latanoprost on cultured human iridal melanocytes. Experimental Eye Research 70 (2000) 113-120
40. Kerstetter J.R., Brubaker R.F., Wilson S.E., and Kullerstrand L.J. Prostaglandin F2-alpha-1-isopropylester lowers intraocular-pressure without decreasing aqueous-humor flow. American Journal of Ophthalmology 105 (1988) 30-34
41. Krauss A.H.P., and Woodward D.F. Update on the mechanism of action of bimatoprost: a review and discussion of new evidence. Survey of Ophthalmology 49 (2004) S5-S11
42. Li N., Chen X.M., Zhou Y., Wei M.L., and Yao X. Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials. Clinical and Experimental Ophthalmology 34 (2006) 755-764
43. Lim K.S., Nau C.B., O'Byrne M.M., Hodge D.O., Toris C.B., McLaren J.W., and Johnson D.H. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects - a crossover study. Ophthalmology 115 (2008) 790-795
44. Lindsey J.D., Kashiwagi K., Boyle D., Kashiwagi F., Firestein G.S., and Weinreb R.N. Prostaglandins increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells. Current Eye Research 15 (1996) 869-875
45. Lindsey J.D., Kashiwagi K., Kashiwagi F., and Weinreb R.N. Prostaglandins alter extracellular matrix adjacent to human ciliary muscle cells in vitro. Investigative Ophthalmology & Visual Science 38 (1997) 2214-2223
46. Lindsey J.D., To H.D., and Weinreb R.N. Induction of C-Fos by prostaglandin-F2-alpha in human ciliary smooth-muscle cells. Investigative Ophthalmology & Visual Science 35 (1994) 242-250
47. Loeffler K.U., Sahm M., and Spitznas M. Short-time application of latanoprost does not stimulate melanogenesis in bovine ocular melanin-containing cells in vitro. Ophthalmic Research 33 (2001) 102-106
48. Lutjen-Drecoll E., and Tamm E. Morphological-study of the anterior segment of cynomolgus monkey eyes following treatment with prostaglandin-F2-alpha. Experimental Eye Research 47 (1988) 761-769
49. McCarey B.E., Kapik B.M., and Kane F.E. Low incidence of iris pigmentation and eyelash changes in 2 randomized clinical trials with unoprostone isopropyl 0.15%. Ophthalmology 111 (2004) 1480-1488
50. Netland P.A., Landry T., Sullivan E.K., Andrew R., Silver L., Weiner A., Mallick S., Dickerson J., Bergamini M.V.W., Robertson S.M., and Davis A.A. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. American Journal of Ophthalmology 132 (2001) 472-484
51. Nilsson S.F.E., Drecoll E., Lutjen-Drecoll E., Toris C.B., Krauss A.H.P., Kharlamb A., Nieves A., Guerra T., and Woodward D.F. The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey. Investigative Ophthalmology & Visual Science 47 (2006) 4042-4049
52. Nilsson S.F.E., Samuelsson M., Bill A., and Stjernschantz J. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F-2-alpha-1-isopropylester in the cynomolgus monkey. Experimental Eye Research 48 (1989) 707-716
53. Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Experimental Eye Research 67 (1998) 179-191
54. Oh D.J., Martin J.L., Williams A.J., Peck R.E., Pokorny C., Russell P., Birk D.E., and Rhee D.J. Analysis of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human ciliary body after latanoprost. Investigative Ophthalmology & Visual Science 47 (2006) 953-963
55. Oh D.J., Martin J.L., Williams A.J., Russell P., Birk D.E., and Rhee D.J. Effect of latanoprost on the expression of matrix metalloproteinases and their tissue inhibitors in human trabecular meshwork cells. Investigative Ophthalmology & Visual Science 47 (2006) 3887-3895
56. Ota T., Aihara M., Narumiya S., and Araie M. The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice. Investigative Ophthalmology & Visual Science 46 (2005) 4159-4163
57. Ota T., Aihara M., Saeki T., Narumiya S., and Araie M. The IOP-lowering effects and mechanism of action of tafluprost in prostanoid receptor-deficient mice. British Journal of Ophthalmology 91 (2007) 673-676
58. Parrish R.K., Palmberg P., and Sheu W.P. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. American Journal of Ophthalmology 135 (2003) 688-703
59. Pfeiffer N., Grierson I., Goldsmith H., Appleton P., Hochgesand D., and Winkgen A. Fine structural evaluation of the iris after unilateral treatment with latanoprost in patients undergoing bilateral trabeculectomy (the Mainz II study). Archives of Ophthalmology 121 (2003) 23-31
60. Pfeiffer N., Grierson I., Goldsmith H., Hochgesand D., Winkgen-Bohres A., and Appleton P. Histological effects in the iris after 3 months of latanoprost therapy - the Mainz 1 Study. Archives of Ophthalmology 119 (2001) 191-196
61. Poyer J.F., Millar C., and Kaufman P.L. Prostaglandin-F2-alpha effects on isolated rhesus-monkey ciliary muscle. Investigative Ophthalmology & Visual Science 36 (1995) 2461-2465
62. Resul B., Stjernschantz J., No K.Y., Liljebris C., Selen G., Astin M., Karlsson M., and Bito L.Z. Phenyl-substituted prostaglandins - potent and selective antiglaucoma agents. Journal of Medicinal Chemistry 36 (1993) 243-248
63. Resul B., Stjernschantz J., Selen G., and Bito L. Structure-activity relationships and receptor profiles of some ocular hypotensive prostanoids. Survey of Ophthalmology 41 (1997) S47-S52
64. Sagara T., Gaton D.D., Lindsey J.D., Gabelt B.T., Kaufman P.L., and Weinreb R.N. Topical prostaglandin F-2 alpha treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Archives of Ophthalmology 117 (1999) 794-801
65. Schachtschabel U., Lindsey J.D., and Weinreb R.N. The mechanism of action of prostaglandins on uveoscleral outflow. Current Opinion in Ophthalmology 11 (2000) 112-115
66. Selen G., Stjernschantz J., and Resul B. Prostaglandin-induced iridial pigmentation in primates. Survey of Ophthalmology 41 (1997) S125-S128
67. Sherwood M., and Brandt J. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Survey of Ophthalmology 45 (2001) S361-S368
68. Stjernschantz J.W. From PGF(2 alpha)-isopropyl ester to latanoprost: a review of the development of Xalatan - the proctor lecture. Investigative Ophthalmology & Visual Science 42 (2001) 1134-1145
69. Stjernschantz J.W., Albert D.M., Hu D.N., Drago F., and Wistrand P.J. Mechanism and clinical significance of prostaglandin-induced iris pigmentation. Survey of Ophthalmology 47 (2002) S162-S175
70. Tamm E., Rittig M., and Lutjen-Drecoll E. Electron microscopy and immunohistochemical studies of the intraocular pressure lowering effect of prostaglandin F2 alpha. Fortschr der Ophthalmol 87 (1990) 623-629
71. Thieme H., Stumpff F., Ottlecz A., Percicot C.L., Lambrou G.N., and Wiederholt M. Mechanisms of action of unoprostone on trabecular meshwork contractility. Investigative Ophthalmology & Visual Science 42 (2001) 3193-3201
72. Toris C.B., Camras C.B., Yablonski M.E., and Brubaker R.E. Effects of exogenous prostaglandins on aqueous humor dynamics and blood-aqueous barrier function. Survey of Ophthalmology 41 (1997) S69-S75
73. Toris C.B., Yablonski M.E., Wang Y.L., and Camras C.B. Aqueous humor dynamics in the aging human eye. American Journal of Ophthalmology 127 (1999) 407-412
74. Wand M., and Gaudio A.R. Cystoid macular edema associated with ocular hypotensive lipids. American Journal of Ophthalmology 133 (2002) 403-405
75. Wand M., and Shields M.B.M. Cystoid macular edema in the era of ocular hypotensive lipids. American Journal of Ophthalmology 133 (2002) 393-397
76. Watson P., et al. A six-month, randomized, double masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology 103 (1996) 126-137
77. Weinreb R.N., Lindsey J.D., and Kashiwagi K. Prostaglandin treatment reduces collagen types I and III in cultures of human ciliary smooth muscle cells. Investigative Ophthalmology & Visual Science 38 (1997) 3782
78. Weinreb R.N., Toris C.B., Gabelt B.T., Lindsey J.D., and Kaufman P.L. Effects of prostaglandins on the aqueous humor outflow pathways. Survey of Ophthalmology 47 (2002) S53-S64
79. Wistrand P.J., Stjernschantz J., and Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Survey of Ophthalmology 41 (1997) S129-S138
80. Woodward D.F., et al. The pharmacology of bimatoprost (Lumigan (TM)). Survey of Ophthalmology 45 (2001) S337-S345
81. Yamamoto T., and Kitazawa Y. Iris-color change developed after topical isopropyl unoprostone treatment. Journal of Glaucoma 6 (1997) 430-432
82. Zimmerman T.J., and Kaufman H.E. Beta-adrenergic blocking-agent for treatment of glaucoma. Archives of Ophthalmology 95 (1977) 601-604